REG - Cambridge Cognition - £1.1 million eCOA contract win

Cambridge Cognition HoldingsAnnouncement

19/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221019:nRSS3270Da&default-theme=true

RNS Number : 3270D  Cambridge Cognition Holdings PLC  19 October 2022

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

£1.1 million eCOA contract win for rare blood disease trial

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that it has
won a £1.1m contract with a major pharmaceutical company to provide
electronic clinical outcome assessments ("eCOA") and hardware for a rare blood
disease study running over the next two years. The new contract, with an
existing customer, is for a mixture of eCOA licenses, services and hardware to
support an upcoming clinical trial.

 

As a leader in digital outcome assessments, Cambridge Cognition primarily
provides cognitive measures and eCOA solutions for clinical trials in central
nervous systems disorders. Impressed by Cambridge Cognition's expertise and
performance in handling multi-site-multi-language studies, the customer has
selected the Company to be the eCOA provider for this trial. This recognition
is important for the Company as the provision of eCOA for clinical trials is a
sizeable growth market, valued at over US$1bn per annum and growing at more
than 15% according to market research(1).

 

Cambridge Cognition has been contracted to provide the platform and the
hardware for capturing participants' experiences as well as their responses to
standardised questionnaires and scales. Cambridge Cognition's experienced
clinical project management team will work closely with the customer to ensure
successful use of the software and devices.

 

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:

"Cambridge Cognition has a strong history of delivering cognitive assessments
in the field, traditionally in clinics and now also at home. We are pleased to
see this new order from an existing client, our reputation for quality,
service and scientific rigour is enabling us to win eCOA-only clinical
trials."

 

References

1.     GrandView Research 2018 eCOA Report

 

For further information, contact:

 

 Cambridge Cognition Holdings Plc                      Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer
 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)  Tel: 020 7886 2500

 Freddy Crossley / Emma Earl                           (Corporate Finance)

 Rupert Dearden                                        (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)                Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)                Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

The information communicated in this announcement contains inside information
for the purposes of Article 7 of the Market Abuse Regulation (EU) No.
596/2014.

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTEAXEPFLKAFFA